Adrenal insufficiency as part of X-linked adrenoleukodystrophy

BACKGROUND: X-linked adrenoleukodystrophy (X-ALD) is a severe neurodegenerative metabolic disease with a frequency 1:17,000 in newborn boys. Being a major part of X-ALD with an incidence of 70–80% of patients, adrenal insufficiency (AI) is a life-threatening condition without timely treatment. The possibility of developing AI during the whole disease duration and the absence of any predictive factor for AI joining shows the necessity of studying AI in X-ALD patients to optimize current diagnostic and treatment algorithms.

AIM: To study diagnostic and therapeutic features of primary adrenal insufficiency due to X-ALD.

MATERIALS AND METHODS: A retrospective observational comparative study was conducted in 66 male patients, examined and treated in the Pediatric endocrinology department of Endocrinology Research Centre, Research Centre for Medical Genetics, Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University Detached Structural Unit Russian Children’s Clinical Hospital (Moscow, Russia) for 2014–2022. All of patients were diagnosed with primary AI and a genetically confirmed X-ALD.

RESULTS: The median age of X-ALD manifestation was 6.6 years [4.7; 11.1]. The earliest age of AI diagnosis was 1.5 years at the preclinical stage and 1 year 8 months with clinical symptoms. The renin level was studied in 22.7% at the manifestation of AI (15/66 patients), mineralocorticoid deficiency was found in 7 patients. Family history was positive in 39.4% of patients (n=66), only in 15.1% (10/66 patients) of patients the disease was established at the preclinical stage. In 59.1% (n=66) the cerebral form of the disease (cALD) was established, in 16.6% — adrenomyeloneuropathy (AMN), and in 24.2% — isolated adrenal insufficiency (PAI). Age of AI establishment in the group of patients with AMN (15.6 years) significantly differs from the establishment of AI in patients with cALD (7.4 years, p=0.001) and PAI (5.6 years, p = 0.000). Mineralocorticoid therapy was prescribed simultaneously with glucocorticoid therapy in patients with cALD, in AMN and PAI patients it was added after 11 and 7 months, respectively (the differences between AMN and PAI groups were insignificant). Combined hormonal therapy receive 41% of patients with cALD, 54.5% of patients with AMN and 60% of patients with PAI.

CONCLUSION: It is necessary to examine all male patients with AI regardless of the manifestation age to exclude adrenoleukodystrophy, and it is also important to examine patients for the presence of AI regardless of X-ALD manifestation age. The assessment of renin level in the manifestation of AI is also needed to prescribe mineralcorticoid therapy timely. Studying family history is the main method to detect X-ALD at the preclinical stage.

1. Engelen M, van Ballegoij WJC, Mallack EJ, et al. International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy. Neurology. 2022;99(21):940-951. doi: https://doi.org/10.1212/WNL.0000000000201374

2. Turk BR, Theda C, Fatemi A, Moser AB. X‐linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci. 2020;80(1):52-72. doi: https://doi.org/10.1002/jdn.10003

3. Ломоносова Е.З., Руденская Г.Е., Шехтер О.В., и др. Клинико-генеалогические, биохимические и молекулярно-генетические характеристики Х-сцепленной адренолейкодистрофии // Медицинская генетика. — 2006. — Т. 5. — №6 (48). — С. 38–47

4. Михайлова С.В. Дифференциальная диагностика наследственных нейрометаболических заболеваний у детей // Российский государственный медицинский университет. — 2010

5. Орлова Е.М. Федеральные клинические рекомендации по ведению детей и подростков с первичной хронической надпочечниковой недостаточностью // Проблемы эндокринологии. — 2013. — Т. 59. — №6. — С. 44–9

6. Орлова Е.М., Карева М.А. Первичная надпочечниковая недостаточность у детей: клинические варианты, диагностика, лечение // Пособие для врачей.— 2008: 51 с.

7. Воинова В.Ю., Школьникова М.А., Николаева Е.А. Возможности новых технологий геномного редактирования в лечении Х-сцепленной адренолейкодистрофии // Российский вестник перинатологии и педиатрии. — 2020. — Т. 65. — №2. — С. 104–7. doi: https://doi.org/10.21508/1027-4065-2020-65-2-104-107

8. Клементьева Н.В., Попов В.С., Исаев А.А., Киселев С.Л. Получение улучшенного варианта вектора для генной терапии Х-сцепленной адренолейкодистрофии // Гены и Клетки. — 2019. — Т. 14. — №3. — C. 112-112. doi: https://doi.org//10.23868/gc122838

9. Новиков П.В., Михайлова С.В., Захарова Е.Ю., Воинова В.Ю. Федеральные клинические рекомендации по диагностике и лечению Х-сцепленной адренолейкодистрофии. Май 2013 г. Доступно на: https://med-gen.ru/docs/adrenoleikodistrofiya.pdf?ysclid=lbvzlttbw113179144

10. Capalbo D, Moracas C, Cappa M, et al. Primary Adrenal Insufficiency in Childhood: Data From a Large Nationwide Cohort. J Clin Endocrinol Metab. 2021;106(3):762-773. doi: https://doi.org/10.1210/clinem/dgaa881

11. Moser AB, Seeger E, Raymond G V. Newborn Screening for X-Linked Adrenoleukodystrophy: Past, Present, and Future. Int J Neonatal Screen. 2022;8(1):16. doi: https://doi.org/10.3390/ijns8010016

12. Lee S, Clinard K, Young SP, et al. Evaluation of X-Linked Adrenoleukodystrophy Newborn Screening in North Carolina. JAMA Netw Open. 2020;3(1):e1920356. doi: https://doi.org/10.1001/jamanetworkopen.2019.20356

13. Schiller S, Henneke M, Gärtner J. Opening New Horizons in the Treatment of Childhood Onset Leukodystrophies. Neuropediatrics. 2019;50(04):211-218. doi: https://doi.org/10.1055/s-0039-1685529

14. Eichler F, Duncan C, Musolino PL, et al. Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med. 2017. doi: https://doi.org/10.1056/nejmoa1700554

15. Burtman E, Regelmann MO. Endocrine Dysfunction in X-Linked Adrenoleukodystrophy. Endocrinol Metab Clin North Am. 2016;45(2):295-309. doi: https://doi.org/10.1016/j.ecl.2016.01.003

16. Huffnagel IC, Laheji FK, Aziz-Bose R, et al. The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration. J Clin Endocrinol Metab. 2019;104(1):118-126. doi: https://doi.org/10.1210/jc.2018-01307

17. Dubey P, Raymond G V., Moser AB, Kharkar S, Bezman L, Moser HW. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr. 2005. doi: https://doi.org/10.1016/j.jpeds.2004.10.067

18. Ryalls MR, Gan H-W, Davison JE. Adrenoleukodystrophy in the Differential Diagnosis of Boys Presenting with Primary Adrenal Insufficiency without Adrenal Antibodies. J Clin Res Pediatr Endocrinol. 2021;13(2):212-217. doi: https://doi.org/10.4274/jcrpe.galenos.2020.2020.0214

19. Polgreen LE, Chahla S, Miller W, et al. Early diagnosis of cerebral X-linked adrenoleukodystrophy in boys with Addison’s disease improves survival and neurological outcomes. Eur J Pediatr. 2011;170(8):1049-1054. doi: https://doi.org/10.1007/s00431-011-1401-1

20. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-389. doi: https://doi.org/10.1210/jc.2015-1710

21. Huffnagel IC, van de Beek M-C, Showers AL, et al. Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy. Mol Genet Metab. 2017;122(4):209-215. doi: https://doi.org/10.1016/j.ymgme.2017.10.012

22. Eyal O, Levin Y, Oren A, et al. Adrenal crises in children with adrenal insufficiency: epidemiology and risk factors. Eur J Pediatr. 2019;178(5):731-738. doi: https://doi.org/10.1007/s00431-019-03348-1